Posted by Michael Wonder on 11 Aug 2022
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
11 August 2022 - First and only approved medicine targeting germline BRCA mutations in high-risk early breast cancer.
Health Canada has granted a Notice of Compliance with Conditions for Lynparza(olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA mutated, human epidermal growth factor receptor 2 negative high-risk early breast cancer who have been treated with neo-adjuvant or adjuvant chemotherapy.
